Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
Received 16 October 2018
Accepted for publication 28 December 2018
Published 16 April 2019 Volume 2019:14 Pages 871—879
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Tai Sun Park,1,* Jieun Kang,2,* Jae Seung Lee,2 Yeon-Mok Oh,2 Sang-Do Lee,2 Sei Won Lee2
1Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea; 2Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
*These authors contributed equally to this work
Background: Frequent development of adverse events and consequent low adherence are major barriers in the wide use of roflumilast. Asian patients may be more susceptible to adverse events due to low BMI. In this study, we aimed to determine if a dose-escalation strategy is useful to improve the drug adherence rate.
Methods: This was a randomized, prospective, open-label, single-blind study to compare the adherence rate to roflumilast according to a dose-escalation or conventional dose strategy in patients with COPD in South Korea. Patients were randomized into two groups (1:1), either roflumilast 500 µg once daily for 12 weeks or roflumilast 250 µg once daily for 4 weeks, and then 500 µg for 12 weeks. The primary outcome was the percentage of patients prematurely discontinuing roflumilast due to adverse events.
Results: A total of 55 patients were randomly assigned to either a conventional-dose group (n=28) or a dose-escalation group (n=27). Discontinuation rates of roflumilast due to adverse events were 46.4% for the conventional-dose group and 59.3% for the dose-escalation group. The median time to discontinuation was not different between groups (58 days for the conventional-dose group, 56 days for the dose-escalation group, p=0.629). In a multivariate analysis, older age was a significant risk factor for drug discontinuation.
Conclusion: High discontinuation rates of roflumilast were observed in both groups regardless of the dose-escalation strategy. The frequent discontinuation suggests that the dose-escalation strategy may not be useful in Asian patients.
Clinical trial: This study is registered at www.ClinicalTrials.gov with identifier number NCT02018432.
Keywords: COPD, roflumilast, adherence
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]